Form 4: Casdin Partners Boosts Stake in Standard BioTools

Casdin Partners and affiliates significantly increased their stake in Standard BioTools Inc. through substantial share purchases in late November 2025.

Summary

• Casdin Partners Master Fund, L.P. acquired 150,000 shares of Standard BioTools Inc. common stock on November 24, 2025, at a weighted average price of $1.4325 per share (ranging from $1.4290 to $1.4396).
• An additional 7,550,000 shares were acquired by Casdin Partners Master Fund, L.P. on November 25, 2025, at a weighted average price of $1.3031 per share (ranging from $1.30 to $1.3843).
• Following these transactions, Casdin Partners Master Fund, L.P. indirectly beneficially owns 71,750,000 shares of common stock.
• Eli Casdin directly owns 2,901,062 shares of common stock.
• Casdin Private Growth Equity Fund II, L.P. indirectly owns 13,939,637 shares of common stock.
• Casdin Private Growth Equity Fund, L.P. indirectly owns 2,744,219 shares of common stock.
• The total beneficial ownership for the group of reporting persons, including direct and indirect holdings, amounts to 91,334,918 shares of Standard BioTools Inc. common stock.
• Eli Casdin is deputized to represent the Reporting Persons on the board of directors of Standard BioTools Inc., leading to all reporting persons being deemed directors by deputization for Section 16 purposes.

Sentiment

Score: 8

Explanation: The substantial increase in beneficial ownership by a major institutional investor and its affiliates, including a director, signals strong confidence in the company's valuation and future prospects. This insider buying is generally viewed as a positive indicator for the stock.

Positives

• Significant insider buying by a major institutional investor and its affiliates, including a director, signals strong confidence in the company's future prospects.
• The purchases represent a substantial increase in beneficial ownership, reinforcing the alignment of interests between the reporting persons and other shareholders.
• The weighted average purchase prices of $1.4325 and $1.3031 suggest these entities see value at these levels.

Future Outlook

NA

Management Comments

• Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer.
• By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, each of the Reporting Persons may be deemed directors by deputization of the Issuer.
• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein.

Industry Context

The significant investment by Casdin Partners, a prominent life sciences investor, suggests continued interest and potential growth opportunities within the biotechnology and life sciences tools sector, where Standard BioTools operates. Such large-scale insider purchases can signal a belief in the long-term value proposition of companies in this innovation-driven industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased confidence due to significant insider investment, potentially signaling undervaluation or strong future performance.
• Management: Stronger alignment with a major institutional investor and board representative.

Key Dates

Recommendation

The significant and substantial purchases by Casdin Partners and its affiliates, including a director, at these price points represent a strong vote of confidence in Standard BioTools Inc. Insider buying of this magnitude often signals that those with the deepest understanding of the company believe the stock is undervalued or poised for future growth. This action suggests a compelling investment opportunity for long-term investors.

Keywords

Standard BioTools, LAB, Casdin Partners, Insider Buying, Beneficial Ownership, SEC Form 4, Equity Investment, Biotech, Life Sciences, Institutional Investor, Director by Deputization